瀚微生物 develops gut microbiome-based therapeutics centered on live microbes and microbial metabolites, with an emphasis on gut–brain axis and immunomodulatory mechanisms. The company’s core business is creating gut bacterial drugs and conducting microbiome-based immunotherapy. Its R&D targets include metabolic diseases, oncology, inflammatory bowel disease, and autoimmune disorders.瀚微生物 has established a diversified pipeline based on microbes and metabolites aiming at immune and neural regulation. Three of its programs, including candidates for depression and autoimmune diseases, have entered investigator-initiated clinical trials (IIT). The company recently completed a Pre‑A financing of over RMB 100 million to accelerate clinical trials and advance early R&D projects; the round was led by a fund under CICC Capital.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2023